Oruka Therapeutics, Inc. financial data

Symbol
ORKA on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
855 Oak Grove Ave., Suite 100, Menlo Park, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
ARCA biopharma, Inc. (to 8/30/2024), NUVELO INC (to 1/27/2009), HYSEQ INC (to 1/28/2003)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.42K % -26.4%
Debt-to-equity 6.57 % +74.6%
Return On Equity -62.9 % -362%
Return On Assets -41.3 % -215%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 35M shares +143%
Common Stock, Shares, Outstanding 35M shares +143%
Entity Public Float 20.9M USD -28.3%
Common Stock, Value, Issued 35K USD +150%
Weighted Average Number of Shares Outstanding, Basic 15M shares +4.19%
Weighted Average Number of Shares Outstanding, Diluted 15M shares +4.19%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 26M USD +2435%
General and Administrative Expense 10.6M USD +70.4%
Operating Income (Loss) -36.6M USD -405%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -54M USD -895%
Earnings Per Share, Basic -1.86 USD/shares -403%
Earnings Per Share, Diluted -1.86 USD/shares -403%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 411M USD +968%
Other Assets, Current 537K USD -10.4%
Assets, Current 413M USD +962%
Property, Plant and Equipment, Net 160K USD +1131%
Operating Lease, Right-of-Use Asset 938K USD +251%
Other Assets, Noncurrent 43K USD +258%
Assets 414M USD +957%
Accounts Payable, Current 571K USD +137%
Employee-related Liabilities, Current 109K USD -42.6%
Liabilities, Current 18M USD +1718%
Operating Lease, Liability, Noncurrent 842K USD +276%
Liabilities 18.9M USD +1453%
Retained Earnings (Accumulated Deficit) -57.9M USD +69.1%
Stockholders' Equity Attributable to Parent 342M USD +802%
Liabilities and Equity 414M USD +957%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.53M USD +4.2%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 545M shares +445%
Common Stock, Shares, Issued 35M shares +143%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.53M USD +4.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 411M USD +968%
Deferred Tax Assets, Valuation Allowance 55.5M USD +2.13%
Deferred Tax Assets, Gross 55.6M USD +2.08%
Operating Lease, Liability 988K USD +228%
Payments to Acquire Property, Plant, and Equipment 2K USD -66.7%
Lessee, Operating Lease, Liability, to be Paid 1.31M USD +284%
Property, Plant and Equipment, Gross 222K USD -3.06%
Operating Lease, Liability, Current 146K USD +89.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 494K USD +415%
Lessee, Operating Lease, Liability, to be Paid, Year One 369K USD +297%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 318K USD +715%
Lessee, Operating Lease, Liability, to be Paid, Year Three 380K USD +280%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 25K USD -75%
Operating Lease, Payments 23K USD -30.3%
Additional Paid in Capital 397M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 63K USD -29.2%
Share-based Payment Arrangement, Expense 9.37M USD +1309%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%